Mylan's Win is Teva's Loss
We're increasing our fair value estimate on the former and decreasing our fair value on the latter, due to Mylan's approval of it generic version of Teva's Copaxone.
Although we have long anticipated a generic Copaxone 40mg approval in the near term,
Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.